 Monotherapy nilutamide pure nonsteroidal antiandrogen untreated patients metastatic carcinoma prostate Italian Prostatic Cancer Project total untreated patients metastatic carcinoma prostate pure nonsteroidal antiandrogen single agent Objective response rate confidence interval Median progression-free survival median survival months patients progression antiandrogen additional objective response second-line endocrine treatment drug patients treatment moderate gastrointestinal symptoms third patients decreased adaptation electroretinogram dark adaptation test presence functional damage visual complaints patients cessation therapy frequent side effects slight nausea patients alcohol intolerance nonsignificant increase testosterone levels month treatment levels stable half active men maintenance libido sexual potency treatment significant increase hemoglobin long term occurrence trophic effect androgens erythropoiesis results nilutamide single agent acceptable toxicity moderate activity sexual interest discrete number cases Whether monotherapy nonsteroidal antiandrogens valid option palliation advanced disease comparative prospective trials